Neupulse raises £918k in a second round of funding

    
January 20, 2023

Neupulse, a University of Nottingham spin out, raised £918k to give people with Tourette’s Syndrome the option to control tics through a wearable.

Neupulse has completed a second round of funding in December 2022. Funds have been raised from existing investors and groups of HNW individuals from around the world

The investment will start the development of the commercially available wearable for use by individuals with Tourettes Syndrome to stop tics.

‘This is an exciting time for the company as move forward to the next stage of our development by starting to design the wearable that will bring choice to thousands of individuals that have Tourettes Syndrome’

Paul Cable, Chief Operating Officer

Since incorporation in March 2021 the company has completed several significant milestones including development of a prototype device for use in a double blinded study, completed the recruitment and are working on analysing the data, the results of the double blinded study, these will be published in Q2 2023 and developed an App to support individuals in recording their tics will go to marketing evaluation in Q1 2023.

Tourette's syndrome is a condition that causes a person to make involuntary sounds and movements called tics. It usually starts during childhood, but the tics and other symptoms usually improve after several years and sometimes go away completely. There's no cure for Tourette's syndrome, but drug or CBiT treatment can help manage symptoms.

Company number: 13198315 

Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road
Nottingham 
England
NG7 2TU

Tourettes Friendly Organisation
All members of the Neurotherapeutics team have completed training with Tourettes Action educating them about Tourettes Syndrome, thus have been awarded with the Tourettes Friendly Organisation badge recognised by Tourettes Action.

Privacy Notice       Cookies

Neupulse and Neutrack are registered trade marks of Neurotherapeutics Ltd

Website by Clifton Media

Back to Top
crossmenu